Mymd Pharmaceuticals IncNASDAQ:MYMD
- LAST PRICE1.9500
- TODAY'S CHANGE (%)0.1000 (5.4054%)
- Bid / Lots1.9500/ 1
- Ask / Lots2.0100/ 1
- Open / Previous Close1.8600 / 1.8500
- Day Range
- 52 Week Range
- Volume8,097
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MYMD |
|---|---|---|
| 09:32 ET | 142 | 1.86 |
| 09:36 ET | 235 | 1.9 |
| 11:09 ET | 632 | 1.89 |
| 11:13 ET | 3305 | 1.96 |
| 11:15 ET | 1500 | 1.97 |
| 11:18 ET | 400 | 2.04 |
| 11:20 ET | 200 | 2.005 |
| 11:44 ET | 600 | 1.95 |
Jun 17, 2024
*DJ MyMD Pharmaceuticals Appoints Mitchell Glass as President and Chief Medical Officer >MYMD, from 9:01AM ET on Monday Jun 17, 2024 by Dow Jones
9:01AM ET on Monday Jun 17, 2024 by Dow JonesMyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer, from 9:00AM ET on Monday Jun 17, 2024 by Dow Jones
9:00AM ET on Monday Jun 17, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mymd Pharmaceuticals Inc | 4.3M | -0.4x | --- |
Genprex Inc | 4.3M | -0.1x | --- |
Portage Biotech Inc | 4.4M | 0.0x | --- |
Protagenic Therapeutics Inc | 4.3M | -0.7x | --- |
Clearmind Medicine Inc | 4.1M | -0.1x | --- |
Theriva Biologics Inc | 4.1M | -0.2x | --- |
Company Information
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Company’s MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. It also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).
Contact Information
- Headquarters
- 855 N. Wolfe Street, Suite 601BALTIMORE, MD, United States 21205
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Joshua Silverman
- President, Director, Chief Medical Officer
- Mitchell Glass
- Interim Chief Financial Officer
- Ian Rhodes
- Executive Vice President - Operations, General Counsel, Chief Legal Officer
- Paul Rivard
- Chief Scientific Officer
- Adam Kaplin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 2.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.17 |
EPS | $-5.53 |
Book Value | $11.17 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
